BiotechTube

Enobosarm + Semaglutide (Wegovy) weekly injection

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obesity & Overweight

Conditions

Obesity & Overweight, Mobility Disability, HOMA-IR

Trial Timeline

Mar 1, 2026 → Dec 1, 2027

NCT ID
NCT07446998

About Enobosarm + Semaglutide (Wegovy) weekly injection

Enobosarm + Semaglutide (Wegovy) weekly injection is a phase 2 stage product being developed by Veru for Obesity & Overweight. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07446998. Target conditions include Obesity & Overweight, Mobility Disability, HOMA-IR.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07446998Phase 2Recruiting

Competing Products

20 competing products in Obesity & Overweight

See all competitors
ProductCompanyStageHype Score
MK0493MerckPhase 2
52
MK0557MerckPhase 3
77
AMG 786AmgenPhase 1
32
Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide PlaceboEli LillyPhase 2
52
TirzepatideEli LillyPhase 2
52
exenatide + PlaceboEli LillyApproved
85
BrenipatideEli LillyPhase 1
33
Orforglipron + PlaceboEli LillyPhase 3
77
TERN-601Terns PharmaceuticalsPhase 2
49
MBX 4291 + PlaceboMBX BiosciencesPhase 1
28
PG-102Rani TherapeuticsPhase 1
25
Orforglipron + PlaceboEli LillyPhase 1
33
Tirzepatide + PlaceboEli LillyPhase 3
77
Eloralintide + PlaceboEli LillyPhase 1
33
Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide PlaceboEli LillyPhase 2
52
LY3437943 + Midazolam + Warfarin + CaffeineEli LillyPhase 1
33
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injectionSkye BiosciencePhase 2
44
TirzepatideEli LillyApproved
85
Adenosine + RegadenosonAstellas PharmaPre-clinical
23
Micafungin + MicafunginAstellas PharmaApproved
85

Other Products from Veru

VERU-111 + Enzalutamide, AbirateronePhase 3
69
VERU-111Phase 3
69
Enobosarm & Abemaciclib Combo + non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or FulvestrantPhase 3
69
Enobosarm + ExemestanePhase 3
69
Sabizabulin + Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulatorPhase 2
44